<DOC>
	<DOC>NCT00240331</DOC>
	<brief_summary>The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.</brief_summary>
	<brief_title>AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male or female subjects with endstage renal failure aged 5080 years, who have received regular haemodialysis treatment for at least 3 months Subjects will have no underlying condition that is expected to limit survival to less than 1 year and is also unrelated to endstage renal disease (ESRD). Subjects should not have received a statin therapy within the past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>End Stage Renal Failure</keyword>
</DOC>